Skip to Content

Generic Eysuvis Availability

Eysuvis is a brand name of loteprednol ophthalmic, approved by the FDA in the following formulation(s):

EYSUVIS (loteprednol etabonate - suspension/drops;ophthalmic)

  • Manufacturer: KALA PHARMS INC
    Approval date: October 26, 2020
    Strength(s): 0.25% [RLD]

Has a generic version of Eysuvis been approved?

No. There is currently no therapeutically equivalent version of Eysuvis available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eysuvis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Nanocrystals, compositions, and methods that aid particle transport in mucus
    Patent 10,058,511
    Issued: August 28, 2018
    Assignee(s): The Johns Hopkins University

    Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

    Patent expiration dates:

    • May 3, 2033
      ✓ 
      Patent use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
      ✓ 
      Drug product
  • Patent 10,646,436

    Patent expiration dates:

    • May 3, 2033
      ✓ 
      Drug product
  • Patent 10,688,045

    Patent expiration dates:

    • May 3, 2033
      ✓ 
      Drug product
  • Nanocrystals, compositions, and methods that aid particle transport in mucus
    Patent 9,056,057
    Issued: June 16, 2015
    Assignee(s): Kala Pharmaceuticals, Inc. The John Hopkins University

    Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

    Patent expiration dates:

    • May 3, 2033
      ✓ 
      Patent use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
      ✓ 
      Drug product
  • Nanocrystals, compositions, and methods that aid particle transport in mucus
    Patent 9,393,213
    Issued: July 19, 2016
    Assignee(s): Kala Pharmaceuticals, Inc.

    Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

    Patent expiration dates:

    • May 3, 2033
      ✓ 
      Drug product
  • Nanocrystals, compositions, and methods that aid particle transport in mucus
    Patent 9,532,955
    Issued: January 3, 2017
    Assignee(s): Kala Pharmaceuticals, Inc. The Johns Hopkins University

    Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

    Patent expiration dates:

    • May 3, 2033
      ✓ 
      Patent use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
  • Nanocrystals, compositions, and methods that aid particle transport in mucus
    Patent 9,737,491
    Issued: August 22, 2017
    Assignee(s): The Johns Hopkins University

    Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

    Patent expiration dates:

    • May 3, 2033
      ✓ 
      Patent use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
  • Compositions and methods for ophthalmic and/or other applications
    Patent 9,827,191
    Issued: November 28, 2017
    Assignee(s): The Johns Hopkins University

    Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.

    Patent expiration dates:

    • May 3, 2033
      ✓ 
      Patent use: A METHOD FOR TREATING DRY EYE IN A PATIENT
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • October 26, 2023 - NEW PRODUCT

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.